Suppliers / Livzon New North River Pharmaceutical

Livzon New North River Pharmaceutical

China Updated 9 July 2026

Livzon New North River Pharmaceutical is an API and finished-dose manufacturer based in China. It holds one active US drug master file across a filed portfolio of 2 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 20 December 2024 as VAI.

1
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
3
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 20 December 2024 VAI US FDA
  • 23 May 2019 NAI US FDA
  • 6 November 2015 NAI US FDA
  • 22 March 2013 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3005619530

What they file, and where

Molecule Regulators Docs
Moxidectin US FDA 1
Tobramycin SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Semaglutide finished dose Tobramycin API

Filings and GMP by regulator

Regulator Filings GMP certificates
ARCSA (EC) 3 None
US FDA None 1

Questions about Livzon New North River Pharmaceutical

Does Livzon New North River Pharmaceutical hold a US DMF or a CEP?
Livzon New North River Pharmaceutical holds 1 active US drug master file. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Livzon New North River Pharmaceutical FDA-registered?
One site operated by Livzon New North River Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Livzon New North River Pharmaceutical's last inspection go?
The most recent inspection on record closed on 20 December 2024 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 4 inspections are on file.
Where does Livzon New North River Pharmaceutical manufacture?
1 registered site is on record, in China (China). Every site is listed on this page with the register it came from.
What does Livzon New North River Pharmaceutical make?
2 molecules are on record against Livzon New North River Pharmaceutical, including Moxidectin and Tobramycin. Each links through to that molecule's full manufacturer list.
Which regulators recognise Livzon New North River Pharmaceutical's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Livzon New North River Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 20 December 2024.

Comparable suppliers

Livzon Group Fuzhou Fuxing Pharmaceutical shares 1 molecule Xellia Pharmaceuticals shares 1 molecule Chongqing Daxin Pharmaceutical shares 1 molecule Minh shares 1 molecule Daxin Pharmaceuticals shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates